The Biomarkers Consortium
Public-Private Partnership Forms The Biomarkers Consortium To Advance The Science Of Personalized Medicine – October 5, 2006
The Foundation for the National Institutes of Health (FNIH), the National Institutes of Health (NIH), the Food and Drug Administration (FDA), and the Pharmaceutical Research and Manufacturers of America (PhRMA) today announced the launch of a major public-private biomedical research partnership, The Biomarkers Consortium, to search for and validate new biological markers ─biomarkers─ to accelerate dramatically the delivery of successful new technologies and medicines for prevention, early diagnosis, and treatment of disease.
Biomarker research already has identified biological indicators that have greatly improved prevention and treatment of disease. Results from consortium projects will be broadly available to researchers worldwide.
Press Conference Video:
.jpg) |
Opening Remarks: Charles Sanders, M.D.
Chairman of the FNIH board of directors
Chairman of The Biomarkers Consortium Executive Committee
View video >
|
.jpg) |
Elias Zerhouni, M.D.
Director, National Institutes of Health
View video >
|
.jpg) |
Andrew C. von Eschenbach, M.D.
Acting Commissioner of Food and Drugs, FDA
View video >
|
.jpg) |
Caroline J. Loew, Ph.D.
Senior Vice President, Scientific and Regulatory Affairs, PhRMA
View video >
|
.jpg) |
Jim Greenwood
President and CEO, Biotechnology Industry Organization (BIO)
View video >
|
.jpg) |
Closing Remarks: Charles Sanders, M.D.
Chairman of the FNIH board of directors
Chairman of The Biomarkers Consortium Executive Committee
View video >
|
Download additional video from the Q&A Session that followed the press conference:
Click here to view the first half of the Q&A Session.
Click here to view the second half of the Q&A Session.
|
Click here to download the full
FNIH press release announcing the collaboration and detailing specifics on the initial projects.
Click here to view a list of
media contacts to address specific media inquiries related to
The Biomarker Consortium.
For related information on innovation.org:
- Backgrounder: Read how this collaboration is working to advance medical science and improve drug discovery and development.
- Fact Sheet: Learn how the search for biomarkers can potentially relieve the burden of diseases such as cancer, depression, and diabetes.
- Executive Committee: View the list of members in this private-public research partnership.
- What the Experts Are Saying: Learn details of the Lung and Lymphoma Projects by reading expert comments.
- Leaders and Experts: Read what experts in the fields of personalized medicine, pharmaceutical development, and medical research are saying about the potential of biomarkers to help diagnose, treat, and prevent disease.
- HHS Statement: Read the published statement from the Secretary of Health and Human Services Mike Leavitt.
Biomarkers are one of several key tools in medical science’s quest for personalized medicine, or the right treatment at the right time for the right patient. Biomarkers help identify patients who will respond to drugs, as well as individuals who are likely to suffer serious side effects.
To find additional information on Personalized Medicine:
